Core Viewpoint - The company emphasizes the accuracy and completeness of its quarterly report, ensuring no false statements or omissions exist, and holds its board and management accountable for the report's content [2][3]. Financial Data - The financial statements for the third quarter are not audited, indicating that the figures presented are preliminary and subject to change [3][7]. - As of the end of the reporting period, the company holds 17,701,793 shares in its repurchase account, representing 2.45% of the total circulating shares [4]. Shareholder Information - The report does not indicate any changes in the top ten shareholders or any significant transactions involving shares lent or returned under the margin trading system [5][6]. Other Important Information - The company has not identified any significant operational issues or additional important information that investors should be aware of during the reporting period [6].
灵康药业集团股份有限公司 2025年第三季度报告